Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

SZSE:300357 Stock Report

Market Cap: CN¥12.0b

Zhejiang Wolwo Bio-Pharmaceutical Future Growth

Future criteria checks 1/6

Zhejiang Wolwo Bio-Pharmaceutical is forecast to grow earnings and revenue by 13.9% and 15.2% per annum respectively. EPS is expected to grow by 13.9% per annum. Return on equity is forecast to be 15.9% in 3 years.

Key information

13.9%

Earnings growth rate

13.87%

EPS growth rate

Pharmaceuticals earnings growth18.2%
Revenue growth rate15.2%
Future return on equity15.94%
Analyst coverage

Low

Last updated08 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Feb 24

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) Shares Could Be 36% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Zhejiang Wolwo Bio-Pharmaceutical fair value estimate is...
Analysis Article • Jan 19

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) Price Is Out Of Tune With Earnings

It's not a stretch to say that Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s ( SZSE:300357 ) price-to-earnings (or...
Analysis Article • Jan 01

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has A Pretty Healthy Balance Sheet

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Sep 30

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) P/E Is Still On The Mark Following 39% Share Price Bounce

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. ( SZSE:300357 ) shares have had a really impressive month, gaining 39...
Analysis Article • Sep 26

These 4 Measures Indicate That Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Is Using Debt Reasonably Well

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jun 30

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. ( SZSE:300357 ) is reducing its dividend from last year's comparable...
Analysis Article • May 27

Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 31x, you may consider...
Analysis Article • May 07

Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)

Key Insights Zhejiang Wolwo Bio-Pharmaceutical's estimated fair value is CN¥30.54 based on 2 Stage Free Cash Flow to...
Analysis Article • Mar 22

Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Earnings and Revenue Growth Forecasts

SZSE:300357 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281,640613N/A6292
12/31/20271,444548N/A5913
12/31/20261,204453N/A4812
3/31/20261,087426266392N/A
12/31/20251,062381271423N/A
9/30/20251,049390247389N/A
6/30/2025980346216361N/A
3/31/2025938315182305N/A
12/31/2024925318133262N/A
9/30/2024905312147291N/A
6/30/2024891311152320N/A
3/31/2024881317145342N/A
12/31/2023848310155382N/A
9/30/2023870292117362N/A
6/30/202389331674358N/A
3/31/2023882328139389N/A
1/1/2023896349160360N/A
9/30/2022888391199369N/A
6/30/2022849372268385N/A
3/31/2022841359183316N/A
12/31/2021808338236361N/A
9/30/2021765324200307N/A
6/30/2021724319183276N/A
3/31/2021691308218288N/A
12/31/2020636278186256N/A
9/30/2020630281183267N/A
6/30/2020624275155251N/A
3/31/2020612274142252N/A
12/31/2019639298N/A233N/A
9/30/2019615290N/A232N/A
6/30/2019556259N/A227N/A
3/31/2019532247N/A197N/A
12/31/2018501233N/A206N/A
9/30/2018478227N/A173N/A
6/30/2018439211N/A169N/A
3/31/2018411200N/A178N/A
12/31/2017386186N/A159N/A
9/30/2017367175N/A150N/A
6/30/2017344154N/A137N/A
3/31/2017324139N/A128N/A
12/31/2016312129N/A123N/A
9/30/2016303129N/A127N/A
6/30/2016283121N/A116N/A
3/31/2016277122N/A121N/A
12/31/2015267118N/A115N/A
9/30/2015261116N/A107N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300357's forecast earnings growth (13.9% per year) is above the savings rate (2.4%).

Earnings vs Market: 300357's earnings (13.9% per year) are forecast to grow slower than the CN market (27.5% per year).

High Growth Earnings: 300357's earnings are forecast to grow, but not significantly.

Revenue vs Market: 300357's revenue (15.2% per year) is forecast to grow slower than the CN market (16.8% per year).

High Growth Revenue: 300357's revenue (15.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300357's Return on Equity is forecast to be low in 3 years time (15.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 16:00
End of Day Share Price 2026/07/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kai WangCitic Securities Co., Ltd.
Zhu ChenCitic Securities Co., Ltd.
Xiao Wei LinEverbright Securities Co. Ltd.